Table 1.
Demographics and clinical characteristics of SSc patients from PRESS and GENISOS cohorts and matched healthy controls at the time of skin biopsy
| Characteristic | PRESS SSc (n=48) |
HC matched to PRESS (n=33) |
GENISOS SSc (n=55) |
HC matched to GENISOS (n=33) |
|---|---|---|---|---|
| Age (years) at biopsy, mean (SD) | 48.0 (15.0) | 47.4 (13.4) | 52.8 (12.6) | 46.8 (11.7) |
| Race/ethnicity, n (%) | ||||
| White | 30 (62.5) | 24 (72.7) | 38 (69.1) | 19 (57.6) |
| Black | 5 (10.4) | 4 (12.1) | 8 (14.5) | 8 (24.2) |
| Hispanic | 9 (18.8) | 4 (12.1) | 9 (16.4) | 6 (18.2) |
| Other | 4 (8.3) | 1 (3.0) | 0 | 0 |
| Female, n (%) | 30 (62.5) | 22 (66.7) | 40 (72.7) | 27 (81.1) |
| Disease duration in years, mean (SD) | 1.3 (0.9) | 7.4 (5.2) | ||
| Diffuse skin involvement, n (%) | 48 (100) | 37 (67.3) | ||
| mRSS, mean (SD) | 21.3 (8.7) | 15.3 (10.4) | ||
| Local skin score, mean (SD) | 1.7 (0.8) | 1.1 (0.9) | ||
| FVC % predicted, mean (SD) | 76.0 (19.8) | 77.3 (19.8) | ||
| SSc-associated autoantibody, n (%)* | ||||
| Antitopoisomerase I | 12/41 (29.3) | 15 (27.3) | ||
| Anti-RNA polymerase III | 17/38 (44.7) | 17 (30.9) | ||
| Anticentromere | 1/36 (2.8) | 7 (12.7) | ||
| Mycophenolate, n (%)† | 19 (39.6) | 4 (7.3) | ||
| Methotrexate, n (%)† | 9 (18.8) | 8 (14.5) | ||
| Cyclophosphamide, n (%)† | 1 (2.1) | 1 (1.8) |
*
indicates positive among those recorded.
†
Indicates patients taking medication at the time of biopsy.
FVC, forced vital capacity; GENISOS, Genetics versus Environment in Scleroderma Outcomes Study; HC, healthy control; mRSS, modified Rodnan Skin Score;PRESS, Prospective Registry for Early Systemic Sclerosis; SSc, systemic sclerosis.